These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37597613)

  • 1. On the (Near) Equivalence of Welfarist and Extra-Welfarist Methods to Value Healthcare With Implications for Assessing Equity.
    Phelps CE
    Value Health; 2023 Nov; 26(11):1601-1607. PubMed ID: 37597613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Values Beyond "Health" in Budget-Constrained Healthcare Systems.
    Phelps CE
    Value Health; 2024 Jul; 27(7):830-836. PubMed ID: 38401798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The social value of mortality risk reduction: VSL versus the social welfare function approach.
    Adler MD; Hammitt JK; Treich N
    J Health Econ; 2014 May; 35():82-93. PubMed ID: 24699210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capabilities as menus: a non-welfarist basis for QALY evaluation.
    Bleichrodt H; Quiggin J
    J Health Econ; 2013 Jan; 32(1):128-37. PubMed ID: 23202258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valuing the benefits and costs of health care programmes: where's the 'extra' in extra-welfarism?
    Birch S; Donaldson C
    Soc Sci Med; 2003 Mar; 56(5):1121-33. PubMed ID: 12593883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Willingness to pay for a QALY: theoretical and methodological issues.
    Gyrd-Hansen D
    Pharmacoeconomics; 2005; 23(5):423-32. PubMed ID: 15896094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-social welfare functions: a reply to Hansen et al.
    Edlin R
    J Health Econ; 2004 Sep; 23(5):899-905. PubMed ID: 15353185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review.
    Ward T; Mujica-Mota RE; Spencer AE; Medina-Lara A
    Pharmacoeconomics; 2022 Jan; 40(1):45-64. PubMed ID: 34713423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring social welfare functions and violation of monotonicity: an example from inequalities in health.
    Abasolo I; Tsuchiya A
    J Health Econ; 2004 Mar; 23(2):313-29; discussion 332-4. PubMed ID: 15019757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention, treatment, and palliative care: The relative value of health improvements under alternative evaluation frameworks.
    Hammitt JK
    J Health Econ; 2022 Jul; 84():102643. PubMed ID: 35688094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Welfarism and extra-welfarism: a critical overview.
    Seixas BV
    Cad Saude Publica; 2017 Aug; 33(8):e00014317. PubMed ID: 28832769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three Pillars of Support for Orphan Drug Programs: Individual Valuations, Societal Valuations, and Anonymous Altruism.
    Lakdawalla DN; Phelps CE; Nguyen HH
    Value Health; 2024 Jul; ():. PubMed ID: 38977180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ramsey waits: allocating public health service resources when there is rationing by waiting.
    Gravelle H; Siciliani L
    J Health Econ; 2008 Sep; 27(5):1143-54. PubMed ID: 18468707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achieving Sustainable Development Goals (SDGs) in Sub-Saharan Africa (SSA): A Conceptual Review of Normative Economics Frameworks.
    Otim ME; Almarzouqi AM; Mukasa JP; Gachiri W
    Front Public Health; 2020; 8():584547. PubMed ID: 33304876
    [No Abstract]   [Full Text] [Related]  

  • 15. Weighting Health Outcomes by Socioeconomic Position Using Stated Preferences.
    Lal A; Siahpush M; Moodie M; Peeters A; Carter R
    Pharmacoecon Open; 2018 Mar; 2(1):43-51. PubMed ID: 29464669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On value frameworks and opportunity costs in health technology assessment.
    Booth N
    Int J Technol Assess Health Care; 2019; 35(5):367-372. PubMed ID: 31530332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On individual preferences and aggregation in economic evaluation in healthcare.
    Liljas B; Lindgren B
    Pharmacoeconomics; 2001; 19(4):323-35. PubMed ID: 11383750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries.
    Kanavos P; Visintin E; Gentilini A
    Soc Sci Med; 2023 Aug; 331():116045. PubMed ID: 37450991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the economic foundations of CEA. Ladies and gentlemen, take your positions!
    Brouwer WB; Koopmanschap MA
    J Health Econ; 2000 Jul; 19(4):439-59. PubMed ID: 11010234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Welfarism versus extra-welfarism: can the choice of economic evaluation approach impact on the adoption decisions recommended by economic evaluation studies?
    Buchanan J; Wordsworth S
    Pharmacoeconomics; 2015 Jun; 33(6):571-9. PubMed ID: 25680402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.